Notizie su Wuxi Apptec H

2359 · HKEX · HKD

Quotazione secondaria. La quotazione principale è WuXi AppTec · SSE (CNY)

215,80 $−1,28%−2,80 $

Chiusura · 7 ottobre 2026

Ultime notizie

Titoli nella lingua originale della fonte.

Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River (si apre in una nuova scheda)
GlobeNewswire · 29 set 2026
Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec (si apre in una nuova scheda)
GlobeNewswire · 24 set 2026
Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave (si apre in una nuova scheda)
GlobeNewswire · 24 set 2026
Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI (si apre in una nuova scheda)
23 set 2026
Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share (si apre in una nuova scheda)
23 set 2026
Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market (si apre in una nuova scheda)
23 set 2026
Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace Disruption (si apre in una nuova scheda)
23 set 2026
Recent Price Trend in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) is Your Friend, Here's Why (si apre in una nuova scheda)
22 set 2026
Capitalize on the ADME-Toxicology Testing Shift: Benchmark Charles River, Thermo Fisher, Eurofins, WuXi AppTec and Evotec to Accelerate R&D ROI and Outpace Disruption (si apre in una nuova scheda)
22 set 2026
Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions (si apre in una nuova scheda)
GlobeNewswire · 10 set 2026
Oligonucleotide Drug Delivery Is Moving Beyond the Liver (si apre in una nuova scheda)
GlobeNewswire · 3 set 2026
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion (si apre in una nuova scheda)
PR Newswire · 31 ago 2026
Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why (si apre in una nuova scheda)
27 ago 2026
Here's Why Momentum in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Should Keep going (si apre in una nuova scheda)
11 ago 2026
Judge blocks US decision to add WuXi to list of firms tied to Chinese military (si apre in una nuova scheda)
7 ago 2026
WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model (si apre in una nuova scheda)
PR Newswire · 3 ago 2026
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year (si apre in una nuova scheda)
PR Newswire · 22 lug 2026
Integrated Development Helps Targeted Protein Degraders Reach the Clinic (si apre in una nuova scheda)
GlobeNewswire · 6 lug 2026
Complex Small Molecules Are Changing Drug R&D (si apre in una nuova scheda)
GlobeNewswire · 26 giu 2026
WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026 (si apre in una nuova scheda)
PR Newswire · 27 apr 2026
Top China Biopharma Stocks to Watch, According to Bernstein (si apre in una nuova scheda)
Investing.com · 30 set 2026